ORMP
NASDAQOramed Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$4.04+0.06 (+1.51%)
01:30 PM07:45 PM
News · 26 weeks25+400%
2026-01-182026-07-12
Mix890d
- Other2(25%)
- SEC Filings2(25%)
- Leadership2(25%)
- Insider2(25%)
Latest news
25 items- PRLifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic FinancingHUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchase agreement with a group of institutional and accredited investors participating in the strategic financing framework established earlier this year with Oramed Pharmaceuticals (NASDAQ:ORMP). "This financing reflects confidence in our strategy and the opportunity ahead," said Mark Grant, President and Chief Executive Officer of Lifeward. "We have built the clinical
- INSIDERCOO & CBO Hexter Joshua sold $611,431 worth of shares (137,000 units at $4.46) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $3.69, decreasing direct ownership by 7% to 1,073,384 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Financial Officer Gabay Avraham sold $330,744 worth of shares (73,360 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 671,785 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- PROramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetSignificant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
- PROramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesNEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Semi-annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranking them by total ma
- SECSEC Form 10-Q filed by Oramed Pharmaceuticals Inc.10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- SECSEC Form NT 10-Q filed by Oramed Pharmaceuticals Inc.NT 10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- INSIDERSEC Form 4 filed by Kidron Nadav4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Miriam4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- SECSEC Form 10-K filed by Oramed Pharmaceuticals Inc.10-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- PRLifeward Successfully Closes on Strategic Partnership with OramedHUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity
- INSIDERSEC Form 4 filed by Gabay Avraham4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Hexter Joshua4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Miriam4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Nadav4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERPresident and CEO Kidron Nadav gifted 100,000 shares, decreasing direct ownership by 3% to 3,255,238 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- PRLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyPositions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- INSIDERPresident and CEO Kidron Nadav converted options into 109,000 shares, increasing direct ownership by 3% to 3,355,238 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Financial Officer Gabay Avraham converted options into 19,000 shares, increasing direct ownership by 3% to 649,256 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Scientific Officer Kidron Miriam converted options into 19,000 shares, increasing direct ownership by 1% to 1,448,664 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERCOO & CBO Hexter Joshua converted options into 19,000 shares, increasing direct ownership by 2% to 1,064,495 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Scientific Officer Kidron Miriam gifted 86,166 shares, decreasing direct ownership by 6% to 1,343,498 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
ORMP FAQ
6 questionsWhat does Oramed Pharmaceuticals Inc. do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral...Where does ORMP stock trade?
Oramed Pharmaceuticals Inc. (ORMP) is listed on NASDAQ.What sector and industry is ORMP in?
Oramed Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ORMP?
Oramed Pharmaceuticals Inc. has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Hold with a $300.00 price target on 2023-01-12.What companies are similar to ORMP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ORMP side-by-side with any of them on Quantisnow.How can I track ORMP on Quantisnow?
Quantisnow aggregates Oramed Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORMP to receive live email and push alerts on every new disclosure.